**Supplementary Table S3.** Subgroup analysis of primary efficacy endpoint in FAS

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | TMF group (n = 93) | | Blank control group (n = 100) | | P |
| Subgroups | No. of Subjects | Subjects with HBV DNA <20 IU/mL at week 48, n (%) | No. of Subjects | Subjects with HBV DNA <20 IU/mL at week 48, n (%) |
| Sex |  |  |  |  |  |
| Male | 45 | 33 (73.3) | 42 | 4 (9.5) | <0.001 |
| Female | 48 | 36 (75.0) | 58 | 5 (8.6) | <0.001 |
| Age |  |  |  |  |  |
| ≤30 years | 13 | 4 (30.8) | 12 | 0 | 0.096 |
| >30 years | 80 | 65 (81.2) | 88 | 9 (10.2) | <0.001 |
| HBeAg |  |  |  |  |  |
| Positive | 23 | 2 (8.7) | 25 | 0 | 0.224 |
| Negative | 69 | 66 (95.7) | 71 | 9 (12.7) | <0.001 |
| HBV-DNA |  |  |  |  |  |
| <8 log10 IU/mL | 72 | 68 (94.4) | 83 | 9 (10.8) | <0.001 |
| ≥8 log10 IU/mL | 21 | 1 (4.8) | 17 | 0 | >0.999 |

FAS: full analysis set; TMF: tenofovir amibufenamide; HBeAg: hepatitis B e-antigen; HBV-DNA: hepatitis B virus DNA.